BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 33709512)

  • 1. Editorial for "Noninvasive Assessment of MGMT Promoter Methylation Status in World Health Organization Grade II-IV Glioma Using Histogram Analysis of Inflow-Based Vascular-Space Occupancy Combined with Structural MR Imaging".
    Politi LS; Pessina F; Simonelli M; Navarria P
    J Magn Reson Imaging; 2021 Jul; 54(1):237-238. PubMed ID: 33709512
    [No Abstract]   [Full Text] [Related]  

  • 2. Noninvasive Assessment of O(6)-Methylguanine-DNA Methyltransferase Promoter Methylation Status in World Health Organization Grade II-IV Glioma Using Histogram Analysis of Inflow-Based Vascular-Space-Occupancy Combined with Structural Magnetic Resonance Imaging.
    He W; Li X; Hua J; Liao S; Guo L; Xiao X; Liu X; Zhou J; Wang W; Xu Y; Wu Y
    J Magn Reson Imaging; 2021 Jul; 54(1):227-236. PubMed ID: 33590929
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of Radiomics Analyses Based on Different Magnetic Resonance Imaging Sequences in Grading and Molecular Genomic Typing of Glioma.
    Huang WY; Wen LH; Wu G; Hu MZ; Zhang CC; Chen F; Zhao JN
    J Comput Assist Tomogr; 2021 Jan-Feb 01; 45(1):110-120. PubMed ID: 33475317
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MRI-Based Deep-Learning Method for Determining Glioma
    Yogananda CGB; Shah BR; Nalawade SS; Murugesan GK; Yu FF; Pinho MC; Wagner BC; Mickey B; Patel TR; Fei B; Madhuranthakam AJ; Maldjian JA
    AJNR Am J Neuroradiol; 2021 May; 42(5):845-852. PubMed ID: 33664111
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Editorial for "Apparent Diffusion Coefficient as Imaging Biomarker for Identifying IDH Mutation, 1p19q Codeletion, and MGMT Promoter Methylation Status in Patients With Glioma".
    Salihoğlu AK; Booth TC
    J Magn Reson Imaging; 2023 Sep; 58(3):739-740. PubMed ID: 36594487
    [No Abstract]   [Full Text] [Related]  

  • 6.
    Kong Z; Lin Y; Jiang C; Li L; Liu Z; Wang Y; Dai C; Liu D; Qin X; Wang Y; Liu Z; Cheng X; Tian J; Ma W
    Cancer Imaging; 2019 Aug; 19(1):58. PubMed ID: 31426864
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The association between
    Okita Y; Shofuda T; Kanematsu D; Yoshioka E; Kodama Y; Mano M; Kinoshita M; Nonaka M; Fujinaka T; Kanemura Y
    Clin Radiol; 2020 Aug; 75(8):622-628. PubMed ID: 32321646
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical implications of TERT promoter mutation on IDH mutation and MGMT promoter methylation in diffuse gliomas.
    Kim HS; Kwon MJ; Song JH; Kim ES; Kim HY; Min KW
    Pathol Res Pract; 2018 Jun; 214(6):881-888. PubMed ID: 29650441
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical insights gained by refining the 2016 WHO classification of diffuse gliomas with: EGFR amplification, TERT mutations, PTEN deletion and MGMT methylation.
    Brito C; Azevedo A; Esteves S; Marques AR; Martins C; Costa I; Mafra M; Bravo Marques JM; Roque L; Pojo M
    BMC Cancer; 2019 Oct; 19(1):968. PubMed ID: 31623593
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sensitivity Analysis of the MGMT-STP27 Model and Impact of Genetic and Epigenetic Context to Predict the MGMT Methylation Status in Gliomas and Other Tumors.
    Bady P; Delorenzi M; Hegi ME
    J Mol Diagn; 2016 May; 18(3):350-361. PubMed ID: 26927331
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic and predictive impact of MGMT promoter methylation in grade 3 gliomas.
    Haque W; Thong E; Andrabi S; Verma V; Brian Butler E; Teh BS
    J Clin Neurosci; 2021 Mar; 85():115-121. PubMed ID: 33581781
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Absence of MGMT promoter methylation in diffuse midline glioma, H3 K27M-mutant.
    Banan R; Christians A; Bartels S; Lehmann U; Hartmann C
    Acta Neuropathol Commun; 2017 Dec; 5(1):98. PubMed ID: 29246238
    [No Abstract]   [Full Text] [Related]  

  • 13. Histogram analysis of 11C-methionine integrated PET/MRI may facilitate to determine the O6-methylguanylmethyltransferase methylation status in gliomas.
    Yu P; Ning J; Xu B; Liu J; Dang H; Lin M; Feng X; Grimm R; Tian J
    Nucl Med Commun; 2019 Aug; 40(8):850-856. PubMed ID: 31135693
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact on prognosis of the regional distribution of MGMT methylation with respect to the CpG island methylator phenotype and age in glioma patients.
    Mur P; Rodríguez de Lope Á; Díaz-Crespo FJ; Hernández-Iglesias T; Ribalta T; Fiaño C; García JF; Rey JA; Mollejo M; Meléndez B
    J Neurooncol; 2015 May; 122(3):441-50. PubMed ID: 25682093
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fusion Radiomics Features from Conventional MRI Predict MGMT Promoter Methylation Status in Lower Grade Gliomas.
    Jiang C; Kong Z; Liu S; Feng S; Zhang Y; Zhu R; Chen W; Wang Y; Lyu Y; You H; Zhao D; Wang R; Wang Y; Ma W; Feng F
    Eur J Radiol; 2019 Dec; 121():108714. PubMed ID: 31704598
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The tumoral A genotype of the MGMT rs34180180 single-nucleotide polymorphism in aggressive gliomas is associated with shorter patients' survival.
    Fogli A; Chautard E; Vaurs-Barrière C; Pereira B; Müller-Barthélémy M; Court F; Biau J; Pinto AA; Kémény JL; Khalil T; Karayan-Tapon L; Verrelle P; Costa BM; Arnaud P
    Carcinogenesis; 2016 Feb; 37(2):169-176. PubMed ID: 26717998
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A multi-sequence and habitat-based MRI radiomics signature for preoperative prediction of MGMT promoter methylation in astrocytomas with prognostic implication.
    Wei J; Yang G; Hao X; Gu D; Tan Y; Wang X; Dong D; Zhang S; Wang L; Zhang H; Tian J
    Eur Radiol; 2019 Feb; 29(2):877-888. PubMed ID: 30039219
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Different diagnostic values of imaging parameters to predict pseudoprogression in glioblastoma subgroups stratified by MGMT promoter methylation.
    Yoon RG; Kim HS; Paik W; Shim WH; Kim SJ; Kim JH
    Eur Radiol; 2017 Jan; 27(1):255-266. PubMed ID: 27048531
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of MGMT promoter methylation sites correlating with gene expression and IDH1 mutation in gliomas.
    Zhang J; Yang JH; Quan J; Kang X; Wang HJ; Dai PG
    Tumour Biol; 2016 Oct; 37(10):13571-13579. PubMed ID: 27468718
    [TBL] [Abstract][Full Text] [Related]  

  • 20. (11)C-methinine uptake correlates with MGMT promoter methylation in nonenhancing gliomas.
    Okita Y; Nonaka M; Shofuda T; Kanematsu D; Yoshioka E; Kodama Y; Mano M; Nakajima S; Kanemura Y
    Clin Neurol Neurosurg; 2014 Oct; 125():212-6. PubMed ID: 25178915
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.